EUCTR2011-001076-18-ES进行中（未招募）1 期
A Phase 2, Randomized, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 at Two Dose Levels in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. At least 18 years of age, or the legal age of consent in the jurisdiction in which the study is taking place
- •2. Eastern Cooperative Oncology Group (ECOG) performance status score 0 to 2
- •3. Histopathologically confirmed CTCL, either mycosis fungoides or Sézary syndrome Stage Ib-IVa
- •4. Relapsed or refractory disease following at least 1 prior systemic therapy for CTCL. PUVA is considered skin-directed therapy and not systemic therapy. Subjects must have recovered from toxicity related to prior systemic therapy after at least 3 weeks wash-out period.
- •5. Stable anti-pruritus regimen (topical corticosteroids or antihistamine) in the preceding 4 weeks
- •6. Measurable disease with at least 1 skin lesion (patch, plaque, or tumor) ? 1 cm in the longest diameter
- •7. Adequate liver function as determined by serum total bilirubin levels ?1.5 x upper limit of normal (ULN), and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ?2.5 x ULN
- •8. Adequate bone marrow function, as determined by an absolute neutrophil count (ANC)?1200/mm3 (or ?1.2x10 to the 9th/L); a platelet count ?100,000/mm3 (or ?100x10 to the 9th/L) and
- •a hemoglobin level greater than 9 g/dL (or?90 g/L), in the absence of transfusion requirements or cytokine support for 7 days prior to enrolling on the study
- •9. Serum potassium, calcium (corrected for albumin level), magnesium must be within institutional normal limits
- •10. LVEF within institutional normal limits, as determined by MUGA or echocardiography
- •11. Adequate renal function as determined by serum creatinine levels ?1.5xULN
- •12. If a woman, before study entry she must be
- •* postmenopausal (> 45 years of age with amenorrhea for at least 18 months)
- •* surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy)
- •* if heterosexually active, practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method, male partner sterilization) before enrollment, throughout the study, and up to 6 months after stopping study drug
- •13. Negative pregnancy test (urine or serum ?-hCG) at Screening (applicable to women of child bearing potential who are sexually active) at most 7 days prior to starting treatment
- •14. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 6 months after receiving the last dose of study drug
- •15. Subjects must have signed an informed consent document indicating that they understand the purpose and procedures required, and are willing to participate in the study
- •16. To participate in the optional pharmacogenomic component of this study, subjects must have signed the informed consent form for pharmacogenomic research indicating willingness to participate in the pharmacogenomic component of the study (where local regulations permit). Refusal to give consent for this component does not exclude a
- •subject from participation in the clinical study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 28
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •1. Prior histone-deacetylase inhibitor therapy for CTCL
- •2. Concurrent systemic corticosteroid dose > 10 mg/day of prednisone or equivalent (stable use of ?10 mg/day of prednisone for ?1 month before study entry is allowed)
- •3. Major surgery or radiotherapy within 3 weeks before study drug administration. Focal radiotherapy for local disease control is allowed. Subjects must have recovered from prior radiotherapy or surgery related toxicity
- •4. Other malignancy within past 5 years. Exceptions include: basal or non-metastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, or Fédération Internationale de Gynécologie et d?Obstétrique Stage 1 carcinoma of the cervix, prostate intraepithelial neoplasia and biochemical relapse free ? 3 years
- •5. Unstable angina or myocardial infarction within the preceding 12 months; congestive heart failure New York Heart Association Class II-IV; known presence of dilated, hypertrophic, or restrictive cardiomyopathy; or any other cardiac abnormality that, in the opinion of the investigator, medical monitor, or consultant cardiologist, may place the subject at an unacceptably increased risk with study drug
- •6. History of any of the following: sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, atrial fibrillation, cardiac arrest, Mobitz II second degree heart block, or third degree heart block; QTc at Screening > 450 ms in males / > 470 ms in females; family history of short QT syndrome, long QT syndrome; obligate use of a
- •cardiac pacemaker. Use of medications that may cause Torsades de Pointes; any of these medications must be discontinued for at least 5 half-lives prior to the first dose of JNJ-26481585.
- •7. Use of potent inhibitors of CYP3A4/A5
- •8. Known HIV/AIDS
- •9. Uncontrolled concurrent illness including, but not limited to, poorly controlled hypertension or diabetes, ongoing clinically significant active infection requiring systemic antibiotics, or psychiatric illness/social situation that may potentially impair subject?s compliance with study procedures
- •10. Planned major surgery during study period
- •11. Inadequate gastrointestinal absorption status (status post-gastrectomy, upper gastrointestinal tract obstruction, inability to swallow)
- •12. Requires hematopoietic growth factors or transfusion of blood products to meet eligibility criteria
- •13. Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study, or prevent the subject from meeting or performing study requirements
- •14. Pregnant or breast-feeding
- •NOTE: Investigators should ensure that all study enrollment criteria have been met at Screening. If a subject's status changes (including laboratory results) after Screening but before first dose of study drug is given such that they now meet an exclusion criterion, they should be excluded from participation in the study.
研究者
相似试验
进行中（未招募）
1 期
A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma (CTCL)EUCTR2011-001076-18-PTJanssen-Cilag International NV46
进行中（未招募）
1 期
A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination with Nivolumab versus Nivolumab Alone in Subjects with Advanced or Metastatic Stomach, Esophageal Cancers who Progressed on or Were Intolerant to 2 or More Previous TherapiesEUCTR2020-004175-41-ITeoImmuneTech, Inc.127
进行中（未招募）
1 期
A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination with Nivolumab versus Nivolumab Alone in Subjects with Advanced or Metastatic Stomach, Esophageal Cancers who Progressed on or Were Intolerant to 2 or More Previous TherapiesAdvanced or metastatic gastric or gastro-esophageal junction (GEJ) or esophageal adenocarcinoma (EAC) progressed on or intolerant to 2 or more prior lines of systemic therapyMedDRA version: 21.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: LLTClassification code 10082464Term: Advanced gastric carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.1Level: LLTClassification code 10084873Term: Gastrooesophageal junction cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10079913Term: Adenocarcinoma of the gastroesophageal junction stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10030145Term: Oesophageal adenocarcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004175-41-ESeoImmuneTech, Inc.127
进行中（未招募）
1 期
I-DXd in Patients With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)MedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864CTIS2024-512368-79-00Daiichi Sankyo Inc.191
招募中
2 期
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Extensive-stage Small Cell Lung CancerJPRN-jRCT2041220019Inoguchi Akihiro80